10x Genomics (TXG) Scheduled to Post Quarterly Earnings on Tuesday

10x Genomics (NASDAQ:TXG - Get Free Report) will be announcing its earnings results after the market closes on Tuesday, April 30th. Analysts expect the company to announce earnings of ($0.46) per share for the quarter. Investors interested in listening to the company's conference call can do so using this link.

10x Genomics (NASDAQ:TXG - Get Free Report) last posted its quarterly earnings results on Thursday, February 15th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.05). The company had revenue of $183.98 million during the quarter, compared to analysts' expectations of $182.73 million. 10x Genomics had a negative return on equity of 28.82% and a negative net margin of 41.17%. 10x Genomics's revenue for the quarter was up 17.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.15) EPS. On average, analysts expect 10x Genomics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

10x Genomics Price Performance

10x Genomics stock traded down $0.22 during mid-day trading on Tuesday, reaching $27.58. The stock had a trading volume of 1,991,437 shares, compared to its average volume of 1,474,930. The company has a market capitalization of $3.29 billion, a price-to-earnings ratio of -12.71 and a beta of 1.90. The company has a 50-day moving average price of $38.95 and a two-hundred day moving average price of $42.81. 10x Genomics has a one year low of $26.75 and a one year high of $63.57.

Insider Activity

In related news, CEO Serge Saxonov sold 1,000 shares of the firm's stock in a transaction on Friday, February 9th. The stock was sold at an average price of $49.53, for a total value of $49,530.00. Following the completion of the sale, the chief executive officer now directly owns 855,381 shares in the company, valued at $42,367,020.93. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, CEO Serge Saxonov sold 1,000 shares of the firm's stock in a transaction on Friday, February 9th. The stock was sold at an average price of $49.53, for a total value of $49,530.00. Following the completion of the sale, the chief executive officer now directly owns 855,381 shares in the company, valued at $42,367,020.93. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Justin J. Mcanear sold 1,865 shares of the firm's stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $46.34, for a total value of $86,424.10. Following the completion of the sale, the chief financial officer now owns 95,240 shares of the company's stock, valued at $4,413,421.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 12,959 shares of company stock worth $592,806. 10.65% of the stock is currently owned by insiders.

Analyst Ratings Changes

TXG has been the topic of several research analyst reports. Barclays lowered their target price on shares of 10x Genomics from $55.00 to $45.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 10th. Deutsche Bank Aktiengesellschaft lowered their target price on shares of 10x Genomics from $60.00 to $55.00 and set a "buy" rating on the stock in a research note on Thursday, April 18th. Finally, Stifel Nicolaus lowered their price objective on shares of 10x Genomics from $68.00 to $63.00 and set a "buy" rating on the stock in a research note on Friday, February 16th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $60.22.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.